Mårten Fernö

Researcher
More filtering options
  1. 32p * biomarkers and molecular subtypes in primary breast tumors and metastases: associations with liver metastases and outcome.

    Siker Kimbung, Kovács, A., Johansson, I., Danielsson, A., Pär-Ola Bendahl, Einbeigi, Z., Mårten Fernö, Hatschek, T. & Ingrid Hedenfalk, 2014, In : Annals of Oncology. 25 Suppl 1, May, p. i11-i12

    Research output: Contribution to journalArticle

  2. AIB1 is a predictive factor for tamoxifen response in premenopausal women.

    Alkner, S., Pär-Ola Bendahl, Grabau, D., Lövgren, K., Stål, O., Lisa Rydén & Mårten Fernö, 2010, In : Annals of Oncology. 21, p. 238-244

    Research output: Contribution to journalArticle

  3. A Molecular Taxonomy for Urothelial Carcinoma.

    Gottfrid Sjödahl, Martin Lauss, Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Oliver Hultman Patschan, Mattias Aine, Mårten Fernö, Markus Ringnér, Wiking Månsson, Fredrik Liedberg, David Lindgren & Mattias Höglund, 2012, In : Clinical Cancer Research. 18, 12, p. 3377-3386

    Research output: Contribution to journalArticle

  4. Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.

    Mårten Fernö, Haglund, M., Pär-Ola Bendahl, Olsson, H. & Lisa Rydén, 2008, In : Läkartidningen. 105, 32-33, p. 2181-2184

    Research output: Contribution to journalArticle

  5. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study

    Falck, A-K., Pär-Ola Bendahl, Christian Ingvar, Isola, J., Jönsson, P-E., Lindblom, P., Lövgren, K., Rennstam, K., Mårten Fernö & Lisa Rydén, 2012, In : BMC Cancer. 12

    Research output: Contribution to journalArticle

  6. A novel model for Ki67 assessment in breast cancer.

    Quinci Romero, Pär-Ola Bendahl, Mårten Fernö, Grabau, D. & Signe Borgquist, 2014, In : Diagnostic Pathology. 9, 1, 118.

    Research output: Contribution to journalArticle

  7. Antibody microarray based oncoproteomics - analysis of breast cancer proteomes

    Carlsson, A., Christer Wingren, Ingvarsson, J., Ellmark, P., Bo Baldetorp, Mårten Fernö, Håkan Olsson & Carl Borrebaeck, 2007, In : Proceedings of the PEPTALK 2007 meeting.

    Research output: Contribution to journalPublished meeting abstract

  8. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

    Siker Kimbung, Markholm, I., Bjöhle, J., Lekberg, T., Wachenfeldt, V. A., Azavedo, E., Saracco, A., Hellström, M., Srinivas Veerla, Paquet, E., Pär Ola Bendahl, Mårten Fernö, Bergh, J., Niklas Loman, Hatschek, T. & Ingrid Hedenfalk, 2018, In : International Journal of Cancer. 142, 3, p. 618-628

    Research output: Contribution to journalArticle

  9. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.

    Klintman, M., Ornbjerg Würtz, S., Christensen, I., Bræmer Hertel, P., Mårten Fernö, Malmberg, M., Mouridsen, H., Cold, F., Schrohl, A-S., Foekens, J., Per Malmström & Brünner, N., 2010, In : Breast Cancer Research and Treatment. 121, p. 365-371

    Research output: Contribution to journalArticle

  10. Association of int2/hst1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis

    A. Borg, Sigurdsson, H., Clark, G. M., M. Ferno, Fuqua, S. A. W., H. Olsson, D. Killander & McGurie, W. L., 1991 Jan 1, In : British Journal of Cancer. 63, 1, p. 136-142

    Research output: Contribution to journalArticle

  11. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers

    Jumppanen, M., Sofia Gruvberger, Kauraniemi, P., Tanner, M., Pär-Ola Bendahl, Lundin, M., Krogh, M., Kataja, P., Åke Borg, Mårten Fernö & Isola, J., 2007, In : Breast Cancer Research. 9, 1

    Research output: Contribution to journalArticle

  12. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group

    Mårten Fernö, Bo Baldetorp, Åke Borg, Brouillet, J. P., Håkan Olsson, Rochefort, H., Sellberg, G., Sigurdsson, H. & Dick Killander, 1994, In : European Journal of Cancer. 30a, 14, p. 2042-2048

    Research output: Contribution to journalArticle

  13. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer

    Rudolph, P., Per Alm, Håkan Olsson, Heidebrecht, H-J., Mårten Fernö, Bo Baldetorp & Parwaresch, R., 2001, In : Human Pathology. 32, 3, p. 311-319

    Research output: Contribution to journalArticle

  14. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.

    Siker Kimbung, Kovács, A., Danielsson, A., Pär-Ola Bendahl, Lövgren, K., Stolt, M. F., Tobin, N. P., Lindström, L., Bergh, J., Einbeigi, Z., Mårten Fernö, Hatschek, T. & Ingrid Hedenfalk, 2015, In : Oncotarget. 6, 32, p. 33306-33318

    Research output: Contribution to journalArticle

  15. Correspondence and Short Communications: Estrogen receptors in gastric cancer

    Jan Johansson, Thulin, L., M Fernö & Andrén-Sandberg, A., 1991, In : Acta oncologica (Stockholm, Sweden). 30, 7, p. 870-2 3 p.

    Research output: Contribution to journalArticle

  16. Cyclin A - an alternative to gene expression profiling for subdividing histological grade 2 breast cancer into groups with different prognosis

    Carina Forsare, AhlinGullers, A., Fjallskog, M. L., Malmstrom, P. & Mårten Fernö, 2010, In : EJC Supplements. 8, 3, p. 95-96

    Research output: Contribution to journalPublished meeting abstract

  17. Cyclin B1 Is an Independent Prognostic Proliferation Marker with a High Reproducibility in a Population-Based Lymph Node Negative Breast Cancer Cohort

    Emma Niméus, Koliadi, A., Ahlin, C., Holmqvist, M., Holmberg, L., Amini, R-M., Jirstrom, K., Warnberg, F., Blomqvist, C., Mårten Fernö & Fjallskog, M-L., 2009, In : Cancer Research. 69, 24, p. 839S-839S

    Research output: Contribution to journalPublished meeting abstract

  18. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

    Emma Niméus, Koliadi, A., Ahlin, C., Holmqvist, M., Holmberg, L., Amini, R-M., Karin Jirström, Wärnberg, F., Blomqvist, C., Mårten Fernö & Fjällskog, M-L., 2010, In : International Journal of Cancer. 127, p. 961-967

    Research output: Contribution to journalArticle

  19. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.

    Berglund, P., Stighall, M., Karin Jirström, Rydén, L., Mårten Fernö, Nordenskjold, B. & Landberg, G., 2008, In : Journal of Clinical Pathology. 61, p. 184-191

    Research output: Contribution to journalArticle

  20. Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study Group

    Bo Baldetorp, Stal, O., Ahrens, O., Cornelisse, C., Corver, W., Falkmer, U. & Mårten Fernö, 1998, In : Cytometry. 33, 4, p. 385-393

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 Next